| Gender Preference | None |
| Age Group | 0 - 99 years |
| Research Start Date | February 18, 2009 |
| Research End Date | February 18, 2019 |
| Principal Investigator | Ayman El-Sheikh, MD |
| Description | Participants in this research study have a favorable histology Wilms tumor that has some risk of returning after treatment. The purpose of this research study is to find out if subjects with a higher risk of having their tumor return will benefit from the addition of doxorubicin or the current standard treatment. Approximately 5 people will take part in this study at the University of Iowa. Study involvement will last for 25 weeks and will have follow-up examinations and tests for about 5 years. |
| Contact Info | Julie de la Garza, 319-356-3749 |
| Keywords | span itemProp='description'>AREN0532 ; cancer ; doxorubicin ; el-sheikh ; IRB#200812777 ; pediatric ; phase 3 ; phase III ; Wilms tumor ; |